^
    Back
    Association details:
    Biomarker:PDGFRA mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Ayvakit (avapritinib) (CSF-1R inhibitor, PDGFR antagonist, mutant c-KIT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

    Excerpt:
    ...The PDGFRα mutation will be identified by local or central assessment, either in an archival tissue sample or a new tumor biopsy obtained prior to treatment with avapritinib....
    Trial ID:
    NAVIGATOR
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

    Excerpt:
    ...Patient has received 3 or more TKI therapies including imatinib, or the patient has GIST that carries a mutation in exon 18 of the PDGFRA gene (such as D842V)....
    Trial ID:
    NCT03862885
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least 3 Prior Lines of Therapy

    Published date:
    01/16/2021
    Excerpt:
    ORR in response-evaluable patients with GIST harboring KIT or non-D842V PDGFRA mutations and with ≥3 prior therapies (n = 103) was 17% (95% CI 10-25)....Avapritinib has manageable toxicity with meaningful clinical activity as fourth-line or later treatment in some patients with GIST with KIT or PDGFRA mutations.
    DOI:
    10.1002/onco.13674